Refining Targeted Therapy Opportunities for BRAF-Mutant Melanoma

Russell W Jenkins; David A Barbie

doi:10.1158/2159-8290.CD-17-0607

Refining Targeted Therapy Opportunities for BRAF-Mutant Melanoma

Cancer Discov. 2017 Aug;7(8):799-801. doi: 10.1158/2159-8290.CD-17-0607.

Authors

Russell W Jenkins^{1

2}, David A Barbie³

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
² Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. dbarbie@partners.org.

PMID: 28765115
DOI: 10.1158/2159-8290.CD-17-0607

Abstract

<b/> Identifying molecular and cellular features associated with resistance to targeted BRAF/MAPK pathway inhibition may guide development of novel therapeutic approaches. Integrated, comparative analysis of genomic and functional data in sensitive and resistant cell lines unveils novel targetable regulators of resistance to MAPK pathway inhibition in melanoma. Cancer Discov; 7(8); 799-801. ©2017 AACR.See related article by Eskiocak et al., p. 832.

Publication types

Comment

MeSH terms

Drug Resistance, Neoplasm / genetics
Humans
MAP Kinase Kinase 1 / genetics
Melanoma / drug therapy*
Melanoma / genetics
Melanoma / pathology
Molecular Targeted Therapy*
Mutation
Proto-Oncogene Proteins B-raf / genetics*

Substances

BRAF protein, human
Proto-Oncogene Proteins B-raf
MAP Kinase Kinase 1